Skip to Main Content

Amicus Therapeutics (FOLD) said Tuesday that its drug for Pompe disease appeared to benefit patients with the disease in a small trial, a modest but noteworthy milestone ahead of what will be a pivotal trial.

“This is an important next step on what’s almost a 20-year journey,” said Amicus CEO John Crowley.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!